AnGes,Inc. Global leader in gene Medical

Select Language




AnGes aims at becoming a “global innovator in the field of gene medicine” and prioritizes, as its most significant strategies, the acquisition of promising seeds (patents or technologies based on which drugs are discovered and developed) that are suited for its product development plan and the alliance for drug development. As of today, several promising seeds have been obtained from universities in Japan and the following alliances have been formed.

AnGes has a technology franchise in the cutting-edge field of gene medicine including gene therapy and nucleic acid medicine and has been leading the world in research and development in this field. As a result, AnGes has accumulated a wide variety of know-how in research and development as well as in technology in the field of gene medicine. Using such intellectual property, AnGes will continue to develop innovative drugs and explore new technologies in the future.

Major Alliance Partners

BioMarin Pharmaceutical Inc. (the United States)

AnGes obtained exclusive rights to market a drug for the treatment of mucopolysaccharidosis VI, Naglazyme®, in Japan from BioMarin Pharmaceutical Inc.

Mitsubishi Tanabe Pharma Corporation

A partnership has been formed for exclusive marketing of HGF Plasmid for the treatment of peripheral arterial disease (PAD) in the United States and japan.


A partnership has been formed for the exclusive worldwide marketing of drugs for external use containing NF-κB decoy oligonucleotide for the indication of skin diseases.

Vical, Inc. (the United States)

AnGes obtained the rights to develop and market cancer treatment drug Allovection in Asia.


  • News Release
  • About AnGes
  • Projects
  • For Investors
  • HomeSite mapPrivacy PolicySite PolicyContact
  • Copyright© AnGes, Inc. All Rights Reserved.